Avalon Globocare Corp
ALBT
View Detailed Chart
2.690USD
-0.030-1.10%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
6.32MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.10%
5 Days
-3.93%
1 Month
+32.51%
6 Months
-58.87%
Year to Date
-17.48%
1 Year
-13.82%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. The company shows very weak stock market performance, in line with its fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Avalon GloboCare Corp. is a commercial-stage company engaged in developing and delivering transformative, precision diagnostics and clinical laboratory services. The Company offers diagnostic testing utilizing proprietary technology to deliver genetics-driven results. It operates through two segments: Real property rental and Lab Services MSO. Lab Services MSO segment is focused on delivering services related to toxicology and wellness testing and provides a portfolio of diagnostic tests including drug testing, toxicology, and a range of test services, from general bloodwork to anatomic pathology, and urine toxicology. Its capabilities include STAT blood testing, qualitative drug screening, genetic testing, urinary testing, and sexually transmitted disease testing. The Lab Services MSO segment is also focused on the commercialization of genetic-based proprietary testing. It is also exploring the commercialization and development of a versatile breathalyzer system, KetoAir breathalyzer.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.33M.
Overvalued
The company’s latest PE is -0.22, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 494.33K shares, increasing 14.69% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.58K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.97.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Avalon GloboCare Corp. is a commercial-stage company engaged in developing and delivering transformative, precision diagnostics and clinical laboratory services. The Company offers diagnostic testing utilizing proprietary technology to deliver genetics-driven results. It operates through two segments: Real property rental and Lab Services MSO. Lab Services MSO segment is focused on delivering services related to toxicology and wellness testing and provides a portfolio of diagnostic tests including drug testing, toxicology, and a range of test services, from general bloodwork to anatomic pathology, and urine toxicology. Its capabilities include STAT blood testing, qualitative drug screening, genetic testing, urinary testing, and sexually transmitted disease testing. The Lab Services MSO segment is also focused on the commercialization of genetic-based proprietary testing. It is also exploring the commercialization and development of a versatile breathalyzer system, KetoAir breathalyzer.
Ticker SymbolALBT
CompanyAvalon Globocare Corp
CEODr. David Jin, M.D., Ph.D.
Websitehttps://www.avalon-globocare.com/
Related Instruments
+1.09%
-0.27%
-0.53%
-0.28%
-0.71%
+0.10%
-0.69%
-10.99%
-0.69%
-0.80%
-0.12%
-0.05%
-0.49%
+1.41%
-0.87%
-2.83%
-0.83%
-0.89%
-1.01%
+0.33%
